Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Prep Pep Access topic
No spam. Unsubscribe anytime.
Debate over pharmacist authority and zero cost-sharing for PREP/PEP as insurers and advocates weigh in
Summary
At a Senate Health & Welfare hearing on H611, Blue Cross Blue Shield raised operational limits to zero cost-share PREP/PEP and noted pharmacy claims lack diagnosis codes; the Healthcare Advocate supported coverage and pharmacist prescribing, while regulators urged further rulemaking and fiscal review before adding pharmacist authority to statute.
The Senate Health & Welfare Committee heard extended testimony on H611 amendments that would protect PREP and PEP coverage and authorize pharmacists to prescribe HIV-prevention medications.
Courtney Harness, representing Blue Cross Blue Shield of Vermont, and Stephanie Ivy, the carrier's director of pharmacy, said their plans perform formulary optimization and have produced savings from biosimilar adoption, but warned that manufacturer pricing remains the principal upstream driver of cost. "We're not seeing a reduction in the manufacturer pricing," Ivy said, noting that plan-level shifts have limited downstream effect.
Ivy also described an operational constraint: pharmacy claims typically lack diagnosis codes that would let payers distinguish PREP or PEP use from HIV treatment. That limitation, she said, would make it difficult to apply targeted zero cost-share rules without extending the benefit across broader drug classes, potentially increasing costs. She cautioned that the amendment's restriction on future utilization management could prevent plans from applying clinically appropriate controls later.
The Office of the Healthcare Advocate supported the proposal. Charles Becker said PREP and PEP are proven, time-sensitive interventions and argued the state should protect them against cost-sharing barriers. "These are safe, effective, well-established interventions," Becker said, urging explicit state protection for PREP and PEP and support for pharmacist prescribing authority if implemented with appropriate payment for clinical services.
State regulators flagged other concerns. A Department of Financial Regulation witness urged consistent statutory definitions (referencing Title 8 chapter 107) and warned a pending federal rule could require states to defray costs of insurance mandates enacted after 2011, raising possible fiscal exposure. Jennifer Poland, director of the Office of Professional Regulation, said OPR supports the policy goals but requested removing or postponing the subsection that would authorize pharmacists to prescribe PREP/PEP because the board of pharmacy and stakeholders have not had time to engage and Title 26 changes may be required.
The Vermont Pharmacist Association urged including pharmacist authority but recommended specifying an implementation timeline for promulgating regulations, pointing to other states' models and a Colorado fiscal note estimating little fiscal impact. Lauren Bod, the association's legislative liaison, asked the committee to set the statute now and allow time for regulator rulemaking.
The committee asked stakeholders to submit written testimony and draft language. No final decisions were taken; members signaled interest in balancing timely access with regulatory and fiscal safeguards.
